在GD2导向的化学抗原受体修饰免疫效应细胞治疗神经母细胞瘤后的18年生存率
Li Che-Hsing1,2,3, Sandhya Sharma1, Andras A Heczey1,2,4
1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston TX.
Research square
|April 25, 2024
概括
长期结果表明,GD2 CAR-T细胞疗法可以导致复发性或耐药性神经母细胞瘤的儿童持续缓解,一些患者超过18年没有疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 儿科医学 儿科医学
背景情况:
- 神经母细胞瘤是一种高风险的儿科癌症.
- 复发性或耐火性神经母细胞瘤的预后不好.
- 化学抗原受体 (CAR) T细胞疗法提供了一个潜在的治疗途径.
研究的目的:
- 评估GD2 CAR-T细胞治疗在儿科神经母细胞瘤患者的长期疗效和安全性.
- 评估CAR-T细胞的响应和持久性的持久性.
- 调查活跃疾病患者与有复发史的患者的结局.
主要方法:
- 一项临床试验涉及EBV特异性T淋巴细胞和CD3激活T细胞,这些T细胞是用GD2向CAR和条形码转基因进行的.
- 治疗给了11名患有活跃神经母细胞瘤的患者和8名有复发史或高复发风险的患者.
- 长期随访长达18年,包括对CAR-T细胞持久性的转基因检测.
主要成果:
- 在11名患有活跃疾病的患者中,有3人实现了完全反应,有2人持续反应 (8岁和18岁以上).
- 8名有复发史或高复发风险的患者中,有5名在输液后10-14年内保持无疾病状态.
- 间歇性检测到转基因持久性,与长期存活相关.
结论:
- 在儿童神经母细胞瘤中,GD2 CAR-T细胞疗法可以实现持久的长期疾病控制.
- 该疗法在复发/耐药病例中显示出持续缓解的潜力.
- 长期持久的CAR-T细胞似乎与持续的生存结果有关.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
